Paxalisib breast cancer data drives Kazia Therapeutics (KZIA) 6-K filing

Rhea-AI Filing Summary

Kazia Therapeutics Limited submitted a Form 6-K to provide investors with a new press release about its cancer drug candidate paxalisib. The release, dated September 11, 2025, is titled “Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy.” The filing makes this press release publicly available as Exhibit 99.1 and incorporates its information, other than a quote from the Chief Executive Officer, into Kazia’s existing Form F-3 registration statement, which may be used for future securities offerings.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2025

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On September 11, 2025, Kazia Therapeutics Limited (the “Company”) issued a press release titled “Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy.” A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company’s registration statement on Form F-3 (File No. 333-281937).

EXHIBIT LIST

Exhibit		Description
99.1		Press Release of Kazia Therapeutics Limited dated September 11, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

/s/ John Friend

John Friend

Chief Executive Officer

Date: September 11, 2025

FAQ

What did Kazia Therapeutics (KZIA) disclose in this Form 6-K?

Kazia Therapeutics Limited furnished a Form 6-K to provide a press release titled “Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy,” dated September 11, 2025, as Exhibit 99.1.

What is the main subject of the Kazia Therapeutics (KZIA) press release attached to the 6-K?

The attached press release discusses complete ex vivo disruption of large circulating tumor cell clusters in stage IV HER2-positive breast cancer using paxalisib monotherapy.

How is this 6-K related to Kazia Therapeutics' (KZIA) Form F-3 registration statement?

Kazia Therapeutics states that the information in this Form 6-K, including Exhibit 99.1 but excluding the quote of Dr. John Friend, is incorporated by reference into its Form F-3 registration statement (File No. 333-281937).

Who signed the Kazia Therapeutics (KZIA) Form 6-K and in what capacity?

The Form 6-K was signed by Dr. John Friend, who is identified as the Chief Executive Officer of Kazia Therapeutics Limited.

What exhibit is included with Kazia Therapeutics' (KZIA) September 2025 Form 6-K?

The Form 6-K includes one exhibit, listed as Exhibit 99.1, which is the press release of Kazia Therapeutics Limited dated September 11, 2025.

Does the Form 6-K indicate whether Kazia Therapeutics (KZIA) files annual reports on Form 20-F or Form 40-F?

The document references the choice between Form 20-F and Form 40-F for annual reports, consistent with foreign private issuer status, in the standard cover information.